Fla. seeking Ameridose clients; Mass. pharmacy recalled all products

Published: Thursday, November 1, 2012 at 5:46 p.m.
Last Modified: Thursday, November 1, 2012 at 5:46 p.m.

Health officials are trying to determine which Florida facilities received products from Ameridose, a Massachusetts pharmacy that has a corporate link to the pharmacy blamed for the fungal meningitis outbreak.

Once identified, these Florida facilities can work with the state to ensure Ameridose products are segregated and handled pursuant to recall procedures, the Florida Department of Health said Thursday.

Florida's move came one day after Ameridose recalled all its products. The pharmacy did so after federal inspectors found fault with its sterility testing processes.

Officials emphasized that no infections have been linked to Ameridose medications.

"Therefore, the FDA has recommended that health care professionals do not need to follow up with patients who have received Ameridose products at this time," the Department of Health said in a news release issued Thursday afternoon.

"However," the release went on to say, "any patients who are experiencing any adverse effects from the products should contact their health care professionals immediately."

Ameridose, based in Westborough, Mass., has the same founders as the New England Compounding Center, whose contaminated steroid medications are blamed for 28 deaths in 19 states, including three in Marion County.

"Health care professionals should cease using any products from Ameridose at this time and should return the products to the company," the release said.

A list of products subject to the recall is available at www.ameridose.com/news/.

Ameridose has no physical presence in Florida; however, it holds two non-resident prescription drug manufacturer permits from the state Department of Business and Professional Regulation and two compounding pharmacy licenses from the Department of Health, the release said.

Reader comments posted to this article may be published in our print edition. All rights reserved. This copyrighted material may not be re-published without permission. Links are encouraged.

▲ Return to Top